Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: jack who wrote (3507)	7/23/1998 10:50:00 PM
From: Prospector	Respond to of 5402

Jack I dug this out of yer Post Prospector Sanguine Corp. (Pasadena, LA County) announced on June 3rd, 1996, that it has signed a contract with the Utah-based Travis Capital Inc. to assist Sanguine in raising $7 million to fund the development of its proprietary red blood cell supplement, PHER-O2. Sanguine was founded in 1991 by the former CEO of Alpha Therapeutic, Thomas Drees. Since then, it has been developing PHER-O2 for use in medical procedures such as transfusions, transplant organ-perfusion, open heart surgery, imaging and angioplasty. Sanguine believes that PHER-O2 has numerous advantages over human blood. In its press release, the company mentioned that PHER-02 carries no blood-borne diseases such as HIV and hepatitis; has the ability to carry three to four times the oxygen of human blood per unit volume; will match all blood types; is amenable to mass production; has a three-year shelf life; and can be stored at room temperature. For more information, contact the company at 818-405-0079.